To usher in the Post-Resistance Era.
By delivering safe, structurally disruptive antimicrobials to millions of patients globally.
01
Structurally disruptive
A multi-site mechanism that attacks the bacterial cell wall directly, leaving pathogens with no evolutionary route around it.
02
Disease-agnostic
One patented composition working across resistant bacteria, enveloped respiratory viruses, and tissue repair.
03
Built for patients
Safe antimicrobials designed to reach millions of people globally, through expedited regulatory pathways.
One engine, advancing three therapeutic fronts.
A single patented composition of methylglyoxal does the work of three programs at once.
01
Antibacterial
Defeats multi-drug-resistant bacteria, including pathogens on the WHO priority list, with no observed evolutionary resistance across two decades.
02
Antiviral
Acts against enveloped respiratory viruses at the point of entry, before infection can take hold.
03
Angiogenic
Promotes angiogenesis and accelerates tissue repair through a regenerative wound-healing pathway.
Drug-resistant infections threaten millions. We are building antimicrobials that pathogens cannot evolve around, and putting them in reach of patients worldwide.